Assure (OTCMKTS:ARHH – Get Rating) and InVivo Therapeutics (NASDAQ:NVIV – Get Rating) are both small-cap medical companies, but which is the better investment? We will contrast the two companies based on the strength of their profitability, institutional ownership, analyst recommendations, risk, valuation, earnings and dividends.
This is a breakdown of current ratings and recommmendations for Assure and InVivo Therapeutics, as provided by MarketBeat.com.
|Sell Ratings||Hold Ratings||Buy Ratings||Strong Buy Ratings||Rating Score|
Volatility & Risk
Assure has a beta of 2.6, suggesting that its stock price is 160% more volatile than the S&P 500. Comparatively, InVivo Therapeutics has a beta of 1.26, suggesting that its stock price is 26% more volatile than the S&P 500.
Insider & Institutional Ownership
0.0% of Assure shares are owned by institutional investors. Comparatively, 18.6% of InVivo Therapeutics shares are owned by institutional investors. 0.1% of InVivo Therapeutics shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock will outperform the market over the long term.
Valuation and Earnings
This table compares Assure and InVivo Therapeutics’ top-line revenue, earnings per share (EPS) and valuation.
|Gross Revenue||Price/Sales Ratio||Net Income||Earnings Per Share||Price/Earnings Ratio|
|Assure||$3.52 million||50.61||-$15.04 million||($0.41)||-7.34|
|InVivo Therapeutics||N/A||N/A||-$9.90 million||N/A||N/A|
InVivo Therapeutics has lower revenue, but higher earnings than Assure.
This table compares Assure and InVivo Therapeutics’ net margins, return on equity and return on assets.
|Net Margins||Return on Equity||Return on Assets|
Assure Company Profile (Get Rating)
Assure Holdings Corp. is a Colorado-based company. It works with neurosurgeons and orthopedic spine surgeons to provide a turnkey suite of services that support intraoperative neuromonitoring activities during invasive surgeries. It focuses primarily on supporting spinal and vascular surgeries, plans are in place to support other classes of medicine that rely on the standard of care that intraoperative neuromonitoring provides. The company was founded by Preston Thomas Parsons on May 24, 2017 and is headquartered in Denver, CO.
InVivo Therapeutics Company Profile (Get Rating)
InVivo Therapeutics Holdings Corp., a research and clinical-stage biomaterials and biotechnology company, engages in developing and commercializing biopolymer scaffolding devices for the treatment of spinal cord injuries (SCI). It is developing a Neuro-Spinal Scaffold implant, which is an investigational bioresorbable polymer scaffold that is designed for implantation at the site of injury within a spinal cord to treat acute SCI. The company was incorporated in 2003 and is headquartered in Cambridge, Massachusetts.
Receive News & Ratings for Assure Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Assure and related companies with MarketBeat.com's FREE daily email newsletter.